These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12783593)

  • 1. Dofetilide: a new drug to control cardiac arrhythmia.
    Elming H; Brendorp B; Pedersen OD; Køber L; Torp-Petersen C
    Expert Opin Pharmacother; 2003 Jun; 4(6):973-85. PubMed ID: 12783593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H; Saliba W
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ; Markham A
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
    Banchs JE; Baquero GA; Nickolaus MJ; Wolbrette DL; Kelleman JJ; Samii S; Grando-Ting J; Penny-Peterson E; Davidson WR; Young SK; Naccarelli GV; Gonzalez MD
    Congenit Heart Dis; 2014; 9(3):221-7. PubMed ID: 23947935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?
    Wolbrette DL; Hussain S; Maraj I; Naccarelli GV
    J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):3-10. PubMed ID: 29940780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.
    Suttorp MJ; Polak PE; van 't Hof A; Rasmussen HS; Dunselman PH; Kingma JH
    Am J Cardiol; 1992 Feb; 69(4):417-9. PubMed ID: 1734660
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
    Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
    LaPointe NM; Pamer CA; Kramer JM
    Pharmacotherapy; 2003 Oct; 23(10):1316-21. PubMed ID: 14594348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
    Falk RH; Pollak A; Singh SN; Friedrich T
    J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dofetilide. UK 68, UK 68798, Tikosyn, Xelide.
    Drugs R D; 1999 Apr; 1(4):304-11. PubMed ID: 10566050
    [No Abstract]   [Full Text] [Related]  

  • 12. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH; Decara JM
    Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dofetilide: is the treatment worse than the disease?
    Lauer MR
    J Am Coll Cardiol; 2001 Mar; 37(4):1106-10. PubMed ID: 11263616
    [No Abstract]   [Full Text] [Related]  

  • 14. Practical approach to the use and monitoring of dofetilide therapy.
    Tran A; Vichiendilokkul A; Racine E; Milad A
    Am J Health Syst Pharm; 2001 Nov; 58(21):2050-9. PubMed ID: 11715827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dofetilide, a new class III antiarrhythmic agent.
    Lenz TL; Hilleman DE
    Pharmacotherapy; 2000 Jul; 20(7):776-86. PubMed ID: 10907968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dofetilide: a class III-specific antiarrhythmic agent.
    Kalus JS; Mauro VF
    Ann Pharmacother; 2000 Jan; 34(1):44-56. PubMed ID: 10669186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dofetilide, a novel class III antiarrhythmic agent.
    Rasmussen HS; Allen MJ; Blackburn KJ; Butrous GS; Dalrymple HW
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S96-105. PubMed ID: 1279316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dofetilide: a new class III antiarrhythmic agent.
    Al-Dashti R; Sami M
    Can J Cardiol; 2001 Jan; 17(1):63-7. PubMed ID: 11173316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.
    Luedtke SA; Kuhn RJ; McCaffrey FM
    Ann Pharmacother; 1997 Nov; 31(11):1347-59. PubMed ID: 9391691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
    Tsikouris JP; Cox CD
    Pharmacotherapy; 2001 Dec; 21(12):1514-29. PubMed ID: 11765303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.